Akanda

Akanda Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Akanda (AKAN) as of Oct 25, 2026 is -2,916.70. In the previous year, Cash Conversion Cycle (CCC) was -1,435.04 — a change of 103.25% (lower).

Cash Conversion Cycle

-2,916.70

YoY

103.25%

Last updated:

Cash Conversion Cycle (CCC) of Akanda is 2025 -2,916.70 . Cash Conversion Cycle (CCC) of Akanda was 2024 -1,435.04 . It decreases by 103.25% lower compared to the previous year.

The Akanda Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2020
-36,981.02 USD
Jan 1, 2021
-234.05 M USD
Jan 1, 2022
-2,789.56 USD
Jan 1, 2023
-794.17 USD
Jan 1, 2024
-1,435.04 USD
Jan 1, 2025
-2,916.70 USD
The Akanda Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-2,916.70+103.25%
-1,435.04+80.70%
-794.17-71.53%
-2,789.56-100.00%
-234.05 M+632,804.39%
-36,981.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Cash Conversion Cycle (CCC) of Akanda is -2,916.70 in 2025.

Cash Conversion Cycle (CCC) of Akanda changed from -1,435.04 to -2,916.70, representing a 103.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Akanda since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Akanda

All Key Metrics — Akanda